Adam P Lightfoot
Overview
Explore the profile of Adam P Lightfoot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millichap L, Turton N, Alomosh R, Heaton R, Bateman A, Al-Shanti N, et al.
Toxicol Mech Methods
. 2025 Mar;
:1-12.
PMID: 40028788
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR) inhibitors, commonly known as statins, are drugs frequently used in the treatment of hypercholesterolemia and hyperlipidemia. However, the current study has demonstrated that simvastatin induces...
2.
Thoma A, Alomosh R, Bond H, Akter-Miah T, Al-Shanti N, Degens H, et al.
J Cell Physiol
. 2024 Oct;
240(1):e31458.
PMID: 39382090
The overexpression of major histocompatibility complex (MHC) I on the surface of muscle fibers is a characteristic hallmark of the idiopathic inflammatory myopathies (IIMs), collectively termed myositis. Alongside MHC-I overexpression,...
3.
Bell G, Thoma A, Hargreaves I, Lightfoot A
Drug Saf
. 2024 Mar;
47(7):643-653.
PMID: 38492173
Statins represent the primary therapy for combatting hypercholesterolemia and reducing mortality from cardiovascular events. Despite their pleiotropic effects in lowering cholesterol synthesis, circulating cholesterol, as well as reducing the risk...
4.
Thoma A, Earl K, Goljanek-Whysall K, Lightfoot A
J Cell Mol Med
. 2022 Nov;
26(24):6032-6041.
PMID: 36426551
Major histocompatibility complex (MHC) I is an important component of intracellular antigen presentation. However, improper expression of MHC I upon the cell surface has been associated with several autoimmune diseases....
5.
Zaabalawi A, Renshall L, Beards F, Lightfoot A, Degens H, Alexander Y, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297480
A significant number of patients with severe cardiovascular disease, undergoing coronary artery bypass grafting (CABG), present with hypertension. While internal mammary arteries (IMAs) may be a better alternative to vein...
6.
Astley C, Houacine C, Zaabalawi A, Wilkinson F, Lightfoot A, Alexander Y, et al.
Biomedicines
. 2021 Dec;
9(12).
PMID: 34944670
Nanostructured lipid carriers (NLCs) are an emerging drug delivery platform for improved drug stability and the bioavailability of antihypertensive drugs and vasoprotective nutraceutical compounds, such as resveratrol (RV). The objective...
7.
Saini J, Faroni A, Reid A, Mouly V, Butler-Browne G, Lightfoot A, et al.
Physiol Rep
. 2021 May;
9(8):e14791.
PMID: 33931983
Neuromuscular junction (NMJ) research is vital to advance the understanding of neuromuscular patho-physiology and development of novel therapies for diseases associated with NM dysfunction. In vivo, the micro-environment surrounding the...
8.
Saini J, Faroni A, Reid A, Mamchaoui K, Mouly V, Butler-Browne G, et al.
J Clin Med
. 2020 Oct;
9(10).
PMID: 33050427
Background: In many neurodegenerative and muscular disorders, and loss of innervation in sarcopenia, improper reinnervation of muscle and dysfunction of the motor unit (MU) are key pathogenic features. studies of...
9.
Thoma A, Lyon M, Al-Shanti N, Nye G, Cooper R, Lightfoot A
Antioxidants (Basel)
. 2020 Aug;
9(8).
PMID: 32764412
Maladaptive endoplasmic reticulum (ER) stress is associated with modified reactive oxygen species (ROS) generation and mitochondrial abnormalities; and is postulated as a potential mechanism involved in muscle weakness in myositis,...
10.
Parkes J, Thoma A, Lightfoot A, Day P, Chinoy H, Lamb J
BMC Rheumatol
. 2020 Jun;
4:25.
PMID: 32529172
Background: The idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune conditions of skeletal muscle inflammation and weakness. MicroRNAs (miRNAs) are short, non-coding RNA which regulate gene expression of target mRNAs. The...